Comparison of Primary and Secondary Prophylaxis Using PEGylated Recombinant Human Granulocyte–Stimulating Factor as a Cost-Effective Measure in Malignant Neoplasms: A Multicenter Retrospective Study

Purpose: The aim of the study was to evaluate the cost-effectiveness of PEGylated recombinant human granulocyte–stimulating factor (PEG-rhG-CSF) as a means of achieving primary and secondary prophylaxis against chemotherapy-induced neutropenia cancer cases. Methods: Individuals who underwent PEG-rhG...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Qiuji, Li, Qiu, Zhang, Jun, Luo, Zhumei, Zhou, Jin, Chen, Jing, Luo, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586644/
https://www.ncbi.nlm.nih.gov/pubmed/34776940
http://dx.doi.org/10.3389/fphar.2021.690874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586644/
https://www.ncbi.nlm.nih.gov/pubmed/34776940
http://dx.doi.org/10.3389/fphar.2021.690874

Ejemplares similares